BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...report. Jeff Cranmer ICON plc Yisheng Biopharma Co. Ltd. Xilio Therapeutics Inc. UCB S.A. Microsoft Corp. Lyvgen Biopharma Co. Ltd. PRA Health Sciences Inc. Truvian Sciences Inc. AmacaThera...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Nets $900M Up Front in Global Deal with Incyte” ). Truvian serology test receives EUA Truvian Sciences Inc....
...ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen Inc. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Shanghai...
Items per page:
1 - 2 of 2
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...report. Jeff Cranmer ICON plc Yisheng Biopharma Co. Ltd. Xilio Therapeutics Inc. UCB S.A. Microsoft Corp. Lyvgen Biopharma Co. Ltd. PRA Health Sciences Inc. Truvian Sciences Inc. AmacaThera...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Nets $900M Up Front in Global Deal with Incyte” ). Truvian serology test receives EUA Truvian Sciences Inc....
...ITMN B) AL001 Boehringer Ingelheim GmbH AbbVie Inc. Eli Lilly and Co. Mirati Therapeutics Inc. Amgen Inc. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Shanghai...
Items per page:
1 - 2 of 2